Plain-English translation of NCT06847542 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new way to treat wet age-related macular degeneration (a condition where abnormal blood vessels grow under the retina and damage vision) using , a medication that stops this abnormal blood vessel growth. Instead of receiving frequent eye injections, participants will have a small implant surgically placed in the eye that slowly releases the medication over several months. The study will measure how well this treatment works, how safe it is, and how it affects patients' quality of life.
Currently, patients with this condition need frequent eye injections — sometimes monthly — which is burdensome and inconvenient. This trial aims to see whether a single surgical implant that delivers medication automatically over a longer period could be more effective and easier for patients to manage.
You likely qualify if…
You likely don't qualify if…
You will have a surgical procedure to implant the device in your eye on the first visit. After that, you'll attend follow-up appointments to check how well the treatment is working and to monitor for any side effects. Depending on how your eye responds at 24 weeks, you may receive refill exchanges (where the implant is refilled or replaced) every 24 or 36 weeks. The entire study lasts about one year, and you'll complete vision tests, eye imaging, and questionnaires about how the treatment affects your daily life throughout the study.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
Austria
Czechia